Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL1B | P01584 | 16/20 | 0.58 |
| ▸ | NLRP3 | Q96P20 | 6/20 | 0.52 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25798372 | 0.86 | IL1B (0.68) | IL1BNLRP3CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL25797976 | 0.86 | IL1B (0.76) | IL1BNLRP3CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL25797975 | 0.85 | IL1B (0.61) | IL1BNLRP3CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL25798326 | 0.83 | IL1B (0.59) | IL1BNLRP3CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL25797913 | 0.83 | IL1B (0.59) | IL1BNLRP3CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL25798122 | 0.81 | IL1B (0.60) | IL1BNLRP3CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL25798377 | 0.81 | IL1B (0.59) | IL1BNLRP3LRRK2 | |
| SCHEMBL25802975 | 0.81 | IL1B (0.78) | IL1BNLRP3 | |
| SCHEMBL25798894 | 0.79 | IL1B (0.67) | IL1BNLRP3CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL25798125 | 0.78 | IL1B (0.67) | IL1BNLRP3CHRNB2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023129987-A1 | PYRIDAZINE DERIVATIVES AS MODULATORS OF NLRP3 INFLAMMASOME AND RELATED METHODS | Neumora Therapeutics, Inc. (US) | 2023-07-06 | — | — | WO | disclosed |